Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A H Sarris

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Leukemia & Lymphoma|May 1, 1995
Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myelomaA H Sarris, A Majlis, M A Dimopoulos, et al.
The Journal of Experimental Medicine|September 1, 1993
Human interferon-inducible protein 10: expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitorsA H Sarris, H E Broxmeyer, U Wirthmueller, et al.
Blood|March 1, 1992
High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemiaA H Sarris, S Kempin, E Berman, et al.
Blood|July 15, 1995
Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma?A H Sarris, T Esgleyes-Ribot, M Crow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphomaP McLaughlin, F B Hagemeister, J E Romaguera, et al.
Cancer|April 1, 1993
Cyclosporine treatment of refractory T-cell lymphomasD L Cooper, I M Braverman, A H Sarris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvementC Visco, L J Medeiros, D Jones, et al.
Investigational New Drugs|January 19, 2000
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combinationJ E Romaguera, M A Rodriguez, F B Hagemeister, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1994
Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3A Younes, J Drach, R Katz, et al.
Leukemia & Lymphoma|June 1, 1997
Primary parotid lymphoma: the effect of International Prognostic Index on outcomeA H Sarris, V Papadimitrakopoulou, M A Dimopoulos, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|May 1, 1995
Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myelomaA H Sarris, A Majlis, M A Dimopoulos, et al.
The Journal of Experimental Medicine|September 1, 1993
Human interferon-inducible protein 10: expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitorsA H Sarris, H E Broxmeyer, U Wirthmueller, et al.
Blood|March 1, 1992
High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemiaA H Sarris, S Kempin, E Berman, et al.
Blood|July 15, 1995
Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma?A H Sarris, T Esgleyes-Ribot, M Crow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphomaP McLaughlin, F B Hagemeister, J E Romaguera, et al.
Cancer|April 1, 1993
Cyclosporine treatment of refractory T-cell lymphomasD L Cooper, I M Braverman, A H Sarris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvementC Visco, L J Medeiros, D Jones, et al.
Investigational New Drugs|January 19, 2000
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combinationJ E Romaguera, M A Rodriguez, F B Hagemeister, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1994
Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3A Younes, J Drach, R Katz, et al.
Leukemia & Lymphoma|June 1, 1997
Primary parotid lymphoma: the effect of International Prognostic Index on outcomeA H Sarris, V Papadimitrakopoulou, M A Dimopoulos, et al.
Pageof 6